Fermenta Biotech is currently trading at Rs. 637.05, up by 34.80 points or 5.78% from its previous closing of Rs. 602.25 on the BSE.The scrip opened at Rs. 615.00 and has touched a high and low of Rs. 648.00 and Rs. 610.00 respectively. So far 6772 shares were traded on the counter.The BSE group `X` stock of face value Rs. 5 has touched a 52 week high of Rs. 1125.00 on 10-Jan-2019 and a 52 week low of Rs. 583.00 on 14-Nov-2019.Last one week high and low of the scrip stood at Rs. 698.00 and Rs. 583.00 respectively. The current market cap of the company is Rs. 623.99 crore.The promoters holding in the company stood at 63.15%, while Institutions and Non-Institutions held 0.55% and 36.30% respectively.Fermenta Biotech has opened a wholly owned subsidiary in Germany, to be closer to its customers. This subsidiary would also manufacture value-added products like D3 500 Feed grade, D3 100 Food grade etc. in Europe through third parties. These value-added products would typically be new variants wherein the company would utilise third party resources in terms of plant, equipment etc. This will strengthen its position in terms of quality, reach and tap into new customers without any additional CAPEX.Fermenta Biotech is manufacturer and supplier of Vitamin D3 (Cholecalciferol), Leading supplier of Penicillin G Amidase, CAL B Lipase, Polymer Supports and enzyme technologies for beta lactams and Bio-Enzymes for Environmental Solutions waste water management and Lake & pond bioremediation.

Fermenta Biotech is currently trading at Rs. 602.00, up by 2.35 points or 0.39% from its previous closing of Rs. 599.65 on the BSE.The scrip opened at Rs. 610.00 and has touched a high and low of Rs. 629.00 and Rs. 583.00 respectively. So far 7374 shares were traded on the counter.The BSE group `X` stock of face value Rs. 5 has touched a 52 week high of Rs. 1125.00 on 10-Jan-2019 and a 52 week low of Rs. 596.00 on 13-Nov-2019.Last one week high and low of the scrip stood at Rs. 716.95 and Rs. 583.00 respectively. The current market cap of the company is Rs. 590.58 crore.The promoters holding in the company stood at 63.15%, while Institutions and Non-Institutions held 0.55% and 36.30% respectively.Fermenta Biotech has opened a wholly owned subsidiary in Germany, to be closer to its customers. This subsidiary would also manufacture value-added products like D3 500 Feed grade, D3 100 Food grade etc. in Europe through third parties. These value-added products would typically be new variants wherein the company would utilise third party resources in terms of plant, equipment etc. This will strengthen its position in terms of quality, reach and tap into new customers without any additional CAPEX.Fermenta Biotech is manufacturer and supplier of Vitamin D3 (Cholecalciferol), Leading supplier of Penicillin G Amidase, CAL B Lipase, Polymer Supports and enzyme technologies for beta lactams and Bio-Enzymes for Environmental Solutions waste water management and Lake & pond bioremediation.

The company witnessed a 18.17% growth in the revenue at Rs. 53.52 millions for the quarter ended June 2019 as compared to Rs. 45.29 millions during the year-ago period.The Net Loss for the quarter ended June 2019 is Rs. -22.31 millions as compared to Net Loss of Rs. -44.20 millions of corresponding quarter ended June 2018Operating profit surged to 16.29 millions from the corresponding previous quarter of 4.75 millions. (Rs. in Million) Quarter ended Year to Date Year ended 201906 201806 % Var 201906 201806 % Var 201903 201803 % Var Sales 53.52 45.29 18.17 53.52 45.29 18.17 193.54 125.08 54.73 Other Income 0.55 0.98 -43.88 0.55 0.98 -43.88 3.23 3.80 -15.00 PBIDT 16.29 4.75 242.95 16.29 4.75 242.95 -59.03 -90.05 -34.45 Interest 41.28 38.79 6.42 41.28 38.79 6.42 159.61 106.34 50.09 PBDT -24.99 -34.04 -26.59 -24.99 -34.04 -26.59 -218.64 -196.39 11.33 Depreciation 9.35 10.16 -7.97 9.35 10.16 -7.97 37.85 38.26 -1.07 PBT -34.34 -44.20 -22.31 -34.34 -44.20 -22.31 -256.49 -234.65 9.31 TAX -12.03 0.00 0.00 -12.03 0.00 0.00 -229.78 6.90 -3430.14 Deferred Tax -12.03 0.00 0.00 -12.03 0.00 0.00 -229.78 0.00 0.00 PAT -22.31 -44.20 -49.52 -22.31 -44.20 -49.52 -26.71 -241.55 -88.94 Equity 45.86 22.93 100.00 45.86 22.93 100.00 45.86 22.93 100.00 PBIDTM(%) 30.44 10.49 190.21 30.44 10.49 190.21 -30.50 -71.99 -57.64

The revenue for the March 2019 quarter is pegged at Rs. 50.79 millions, about 11.06% up against Rs. 45.73 millions recorded during the year-ago period.The Total Profit for the quarter ended March 2019 of Rs. 189.68 millions grew from Rs.-103.42 millions Operating profit Margin for the quarter ended March 2019 improved to 9.92% as compared to -48.75% of corresponding quarter ended March 2018 (Rs. in Million) Quarter ended Year to Date Year ended 201903 201803 % Var 201903 201803 % Var 201803 201703 % Var Sales 50.79 45.73 11.06 193.54 125.49 54.23 125.08 55.15 126.80 Other Income 1.04 2.37 -56.12 3.22 3.40 -5.29 3.80 4.50 -15.56 PBIDT 9.92 -48.75 -120.35 -59.03 -90.04 -34.44 -90.05 -80.36 12.06 Interest 40.07 37.71 6.26 159.62 106.35 50.09 106.35 64.90 63.87 PBDT -30.15 -86.46 -65.13 -218.65 -196.39 11.33 -196.40 -145.26 35.21 Depreciation 9.95 10.06 -1.09 37.85 38.26 -1.07 38.26 34.48 10.96 PBT -40.10 -96.52 -58.45 -256.49 -234.65 9.31 -234.65 -179.74 30.55 TAX -229.78 6.90 -3430.14 -229.78 6.90 -3430.14 6.90 3.28 110.37 Deferred Tax -229.78 0.00 0.00 -229.78 0.00 0.00 0.00 0.00 0.00 PAT 189.68 -103.42 -283.41 -26.71 -241.55 -88.94 -241.55 -183.02 31.98 Equity 45.86 22.93 100.00 45.86 22.93 100.00 22.93 22.93 0.00 PBIDTM(%) 19.53 -106.60 -118.32 -30.50 -71.75 -57.49 -71.99 -145.71 -50.60

DIL is currently trading at Rs. 737.90, up by 11.70 points or 1.61% from its previous closing of Rs. 726.20 on the BSE.The scrip opened at Rs. 722.10 and has touched a high and low of Rs. 737.90 and Rs. 722.10 respectively. So far 278 shares were traded on the counter.The BSE group `X` stock of face value Rs. 5 has touched a 52 week high of Rs. 1125.00 on 10-Jan-2019 and a 52 week low of Rs. 622.50 on 23-May-2018.Last one week high and low of the scrip stood at Rs. 741.95 and Rs. 722.10 respectively. The current market cap of the company is Rs. 663.19 crore.The promoters holding in the company stood at 62.59%, while Institutions and Non-Institutions held 0.33% and 37.08% respectively.DIL’s subsidiary -- Fermenta Biotech has been certified as Great Place to Work by a Global authority (Great Place to Work). This recognition is considered as the `Gold Standard` in `Employer of Choice` recognitions.DIL is engaged in the business of research support services through their subsidiary Research Support International (RSIL), manufacture and marketing of enzymes and chemicals through their subsidiary Fermenta Biotech (FBL).

The Turnover for the quarter ended December 2018 of Rs. 48.96 millions increase by 53.82% from Rs. 31.83 millions.The Net Loss for the quarter ended December 2018 is Rs. -40.17 millions as compared to Net Loss of Rs. -38.93 millions of corresponding quarter ended December 2017 Operating profit Margin for the quarter ended December 2018 improved to 9.37% as compared to -9.96% of corresponding quarter ended December 2017 (Rs. in Million) Quarter ended Year to Date Year ended 201812 201712 % Var 201812 201712 % Var 201803 201703 % Var Sales 48.96 31.83 53.82 142.75 79.76 78.97 125.08 55.15 126.80 Other Income 0.38 0.43 -11.63 2.18 1.03 111.65 3.80 4.50 -15.56 PBIDT 9.37 -9.96 -194.08 -68.95 -41.29 66.99 -90.05 -80.36 12.06 Interest 40.99 19.56 109.56 119.55 68.64 74.17 106.35 64.90 63.87 PBDT -31.62 -29.52 7.11 -188.50 -109.93 71.47 -196.40 -145.26 35.21 Depreciation 8.55 9.41 -9.14 27.90 28.20 -1.06 38.26 34.48 10.96 PBT -40.17 -38.93 3.19 -216.39 -138.13 56.66 -234.65 -179.74 30.55 TAX 0.00 0.00 0.00 0.00 0.00 0.00 6.90 3.28 110.37 Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT -40.17 -38.93 3.19 -216.39 -138.13 56.66 -241.55 -183.02 31.98 Equity 45.86 22.93 100.00 45.86 22.93 100.00 22.93 22.93 0.00 PBIDTM(%) 19.14 -31.29 -161.16 -48.30 -51.77 -6.70 -71.99 -145.71 -50.60

DIL is currently trading at its upper circuit limit of Rs. 1045.10, up by 49.75 points or 5.00% from its previous closing of Rs. 995.35 on the BSE.The scrip opened at Rs. 1045.10 and has touched a high and low of Rs. 1045.10 and Rs. 1045.10 respectively.The BSE group `XT` stock of face value Rs. 10 has touched a 52 week high of Rs. 1070.00 on 11-Oct-2017 and a 52 week low of Rs. 590.00 on 04-Sep-2017.Last one week high and low of the scrip stood at Rs. 1070.00 and Rs. 748.00 respectively. The current market cap of the company is Rs. 239.66 crore.The promoters holding in the company stood at 62.59%, while institutions and non-institutions held 0.01% and 37.40% respectively.DIL has received an approval to sign a Term Sheet to acquire 3,830,072 equity shares in its subsidiary, Fermenta Biotech (FBL), representing 21.05% of the issued and paid-up capital of FBL, from Evolvence India Life Sciences Fund LLC, a Private Equity Investor. The Board of Directors of the company at its meeting held on October 11, 2017 have authorised the same. DIL (earlier known as Duphar-Interfran) is a well-respected public listed company. It has built a stellar reputation for itself in the arenas of pharmaceuticals, biotechnology, environmental solutions and other segments including Entertainment and Health & Wellness.

Dil has submitted a copy of Standalone & Consolidated Statement on Impact of Audit Qualifications for the period ended March 31, 2016.The above information is a part of company’s filings submitted to BSE.

Dil has informed that the 63rd Annual General Meeting (AGM) of the Company was held on September 30, 2015.The above information is a part of company’s filings submitted to BSE.

Dil has informed about the details of voting results at the Annual General Meeting (AGM) of the Company held on September 30, 2015, under Clause 35A of Listing Agreement.The above information is a part of company’s filings submitted to BSE.

Dil has informed that a meeting of the Audit Committee and Board of Directors of the Company is scheduled to be held on August 14, 2015, to consider and approve unaudited financial results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2015. Further, in compliance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and the Company’s Code of Conduct to Regulate, Monitor and Report Trading by Insiders, it is hereby notified that ‘Trading Window’ (period for trading in Company’s securities) shall be closed from August 06,2015 till expiry of 24 hours from the close of business hours on the date of the ensuing Board Meeting to be held on August 14, 2015, for approval of the unaudited financial results (Standalone and Consolidated) of the Company, for the quarter ended June 30,2015. During the closure of Trading Window, all Directors, Promoters, Insiders, Designated Persons including Auditors shall not, directly or indirectly trade or deal or enter into any transaction involving sale or purchase of the Company’s Equity Shares, either in their own name or in the name of their Immediate Relatives.The above information is a part of company’s filings submitted to BSE.

Dilhas informed that the 62nd Annual General Meeting (AGM) of the Company was held on September 24, 2014.The above information is a part of company’s filings submitted to BSE